bisnorcymserine
AssetAlso BNC
Selective butyrylcholinesterase inhibitor
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- BCHE
- 0
- Indications
- 1
- Trial
- 1
- Developer
Indications
1No named disease
Phase 1, Completed, NCT01747213, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.